R&D: Galapagos Expands R&D Facility in Croatia

Belgium firm Galapagos, a clinical stage biotech company focused on developing novel medicines has launched new drug discovery service company, Fidelta at its research site in Zagreb.

Galapagos acquired GlaxoSmithKline’s state-of-the-art research centre in Zagreb in September 2010 accessing capabilities to resource research programs from molecule through to the clinic for internal R&D programmes.

Fidelta will be Galapagos’s third service division alongside BioFocus and Argenta. Galapagos says Fidelta is an exciting new drug discovery service company, being launched in the year that Croatia joins the European Union…

See more